1. Home
  2. NNDM vs DMAC Comparison

NNDM vs DMAC Comparison

Compare NNDM & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nano Dimension Ltd.

NNDM

Nano Dimension Ltd.

N/A

Current Price

$1.33

Market Cap

606.7M

Sector

Technology

ML Signal

N/A

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

N/A

Current Price

$9.49

Market Cap

501.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NNDM
DMAC
Founded
2012
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
606.7M
501.0M
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
NNDM
DMAC
Price
$1.33
$9.49
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $15.50
AVG Volume (30 Days)
★ 1.2M
214.7K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $102,437,000.00
$500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.00
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 77.30
N/A
52 Week Low
$1.19
$5.25
52 Week High
$2.32
$11.00

Technical Indicators

Market Signals
Indicator
NNDM
DMAC
Relative Strength Index (RSI) 40.16 57.22
Support Level $1.32 $5.86
Resistance Level $1.62 N/A
Average True Range (ATR) 0.06 0.73
MACD -0.01 0.04
Stochastic Oscillator 47.83 54.49

Price Performance

Historical Comparison
NNDM
DMAC

About NNDM Nano Dimension Ltd.

Nano Dimension Ltd provides industrial manufacturing solutions for the design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, and industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research, and academia, along with government organizations.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: